WuXi AppTec Gains China Rights To AutoGenomics' Molecular Diagnostic Platform

WuXi AppTec, China's largest CRO/CMO, announced a strategic collaboration with AutoGenomics, a San Diego-area molecular diagnostic company. WuXi's Laboratory Testing Division will own China rights to manufacture and distribute AutoGenomics' INFINITIĀ® molecular diagnostic systems, a microarray platform with 65 clinical tests currently. WuXi is making a concerted effort to become a major player in China's diagnostic sector, initially as a clinical service provider and now it has added device manufacturer.

Back to news